Skip to main content

Bigfoot Biomedical

By Jessica Hagen | 03:20 pm | February 13, 2023
The Omnipod maker purchased assets related to Bigfoot Biomedical's pump-based automated insulin delivery technology.
By Mallory Hackett | 12:58 pm | May 10, 2021
The system was cleared for use among individuals 12 years old and up with Type 1 or Type 2 diabetes on multiple-dose injection therapy.  
By Laura Lovett | 02:55 pm | June 03, 2020
Pharma giant Abbott led the round with participation from Quadrant Capital Advisors Senvest Capital, Janus Henderson, Cormorant Asset Management and other funders. 
By Dave Muoio | 12:31 pm | January 16, 2020
Bigfoot has agreed to develop and commercialize new programs that will integrate with Abbott's diabetes management platform.